RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19, Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial

Preliminary analysis found no significant difference in 28-day mortality (20% colchicine vs. 19% usual care alone; risk ratio 1.02 [95% CI 0.94-1.11]; p=0.63). On the advice of the independent Data Monitoring Committee, recruitment to this arm of the study has closed.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news